Haematologica (Jun 2022)
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
- Naseema Gangat,
- Isla Johnson,
- Kristen McCullough,
- Faiqa Farrukh,
- Aref Al-Kali,
- Hassan Alkhateeb,
- Kebede Begna,
- Abhishek Mangaonkar,
- Mark Litzow,
- William Hogan,
- Mithun Shah,
- Mrinal Patnaik,
- Animesh Pardanani,
- Ayalew Tefferi
Affiliations
- Naseema Gangat
- Division of Hematology, Mayo Clinic, Rochester, MN
- Isla Johnson
- Division of Hematology, Mayo Clinic, Rochester, MN
- Kristen McCullough
- Division of Hematology, Mayo Clinic, Rochester, MN
- Faiqa Farrukh
- Division of Hematology, Mayo Clinic, Rochester, MN
- Aref Al-Kali
- Division of Hematology, Mayo Clinic, Rochester, MN
- Hassan Alkhateeb
- Division of Hematology, Mayo Clinic, Rochester, MN
- Kebede Begna
- Division of Hematology, Mayo Clinic, Rochester, MN
- Abhishek Mangaonkar
- Division of Hematology, Mayo Clinic, Rochester, MN
- Mark Litzow
- Division of Hematology, Mayo Clinic, Rochester, MN
- William Hogan
- Division of Hematology, Mayo Clinic, Rochester, MN
- Mithun Shah
- Division of Hematology, Mayo Clinic, Rochester, MN
- Mrinal Patnaik
- Division of Hematology, Mayo Clinic, Rochester, MN
- Animesh Pardanani
- Division of Hematology, Mayo Clinic, Rochester, MN
- Ayalew Tefferi
- Division of Hematology, Mayo Clinic, Rochester, MN
- DOI
- https://doi.org/10.3324/haematol.2022.281214
- Journal volume & issue
-
Vol. 107,
no. 10
Abstract
No abstracts available.
